Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Celyad S A currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner, MOSELEY II, NELSON B, which indicates a focused prosecution strategy. Because the portfolio is concentrated under 1 distinct examiner, the company's legal approach can be tailored to the individual preferences and historical patterns of this examiner. This centralization of the prosecution process can lead to direct communication and a uniform strategy across the company's pending intellectual property.
The portfolio is also restricted to 1 distinct art unit, suggesting that the technology is specialized within its field. MOSELEY II, NELSON B is identified as the busiest examiner, holding 1 pending action. This means that the company's current patent trajectory is tied to the outcome of this specific case. For a practitioner, this concentration emphasizes the need for a thorough analysis of the specific art unit's guidelines, as the presence of 1 distinct examiner means there is no opportunity to test different arguments across various examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSELEY II, NELSON B | 1 | 68.0% | +41.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18125762 | REDUCING FRATRICIDE OF IMMUNE CELLS EXPRESSING NKG2D-BASED RECEPTORS | MOSELEY II, NELSON B | 28d |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18125762 | REDUCING FRATRICIDE OF IMMUNE CELLS EXPRESSING NKG2D-BASED RECEPTORS | MOSELEY II, NELSON B | 1642 | §112DP | Final Rejection | 28d | Pending | Mar 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial